Department of Ophthalmology, Changzheng Hospital of Naval Medical University, Shanghai, China.
92882 Troops of the Chinese People's Liberation Army, Qingdao, China.
Front Immunol. 2023 Jun 9;14:1194590. doi: 10.3389/fimmu.2023.1194590. eCollection 2023.
Retinoblastoma (RB) and uveal melanoma (UM) are the most common primary intraocular tumors in children and adults, respectively. Despite continued increases in the likelihood of salvaging the eyeball due to advancements in local tumor control, prognosis remains poor once metastasis has occurred. Traditional sequencing technology obtains averaged information from pooled clusters of diverse cells. In contrast, single-cell sequencing (SCS) allows for investigations of tumor biology at the resolution of the individual cell, providing insights into tumor heterogeneity, microenvironmental properties, and cellular genomic mutations. SCS is a powerful tool that can help identify new biomarkers for diagnosis and targeted therapy, which may in turn greatly improve tumor management. In this review, we focus on the application of SCS for evaluating heterogeneity, microenvironmental characteristics, and drug resistance in patients with RB and UM.
视网膜母细胞瘤 (RB) 和葡萄膜黑色素瘤 (UM) 分别是儿童和成人中最常见的原发性眼内肿瘤。尽管由于局部肿瘤控制的进步,眼球挽救的可能性不断增加,但一旦发生转移,预后仍然很差。传统的测序技术从不同细胞的聚集物中获取平均信息。相比之下,单细胞测序 (SCS) 允许在单个细胞的分辨率下研究肿瘤生物学,深入了解肿瘤异质性、微环境特性和细胞基因组突变。SCS 是一种强大的工具,可以帮助识别用于诊断和靶向治疗的新生物标志物,这反过来又可能极大地改善肿瘤管理。在这篇综述中,我们重点介绍了 SCS 在评估 RB 和 UM 患者的异质性、微环境特征和耐药性方面的应用。